I would suggest that since the “ resignations” of the directors today esp Sinclair that even this “analysis” will be canned .
“Accordingly, the Company has engaged a specialised global healthcare intelligence group to undertake an analysis on the potential future risks to the addressable market for PresendinTM for IIH. The results of the analysis will be available in mid Q3 CY2023. The Board will then be in a position to fully assess the market opportunity for PresendinTM in IIH in light of new GLP-1RAs including Ozempic® and Wegovy® and whether to continue with the revised protocol change for the IIH EVOLVE Phase III trial “
Twiggy's Invex Therapeutics | The Imminent Coin Flip, page-212
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable